Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 30, 2026 08:05 ET | Source: Sangamo Therapeutics, Inc.

Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)

SANGAMO THERAPEUTICS TO PRESENT PIPELINE AND TECHNOLOGY ADVANCES AT THE 29TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT)
April 30, 2026 08:00 ET | Source: Solid Biosciences Inc.

Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy

- Solid Biosciences delivers its largest scientific program at the 2026 ASGCT Annual Meeting with 5 oral presentations and 11 posters - CHARLESTOWN, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Solid...
April 30, 2026 08:00 ET | Source: Elicio Therapeutics Inc.

Elicio Therapeutics to Present at the Bank of America Healthcare Conference

BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies...
April 30, 2026 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to...
April 29, 2026 09:00 ET | Source: Codexis, Inc.

Codexis to share RNA manufacturing advances at TIDES USA

REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS) a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, will present...
April 29, 2026 07:05 ET | Source: Anika Therapeutics Inc.

Anika Reports First Quarter 2026 Financial Results

Grew total company revenue 13%, driven by Commercial Channel strength and favorable OEM Channel order timing Delivered 64% gross margin, +8 points year over year, driven by improved operational...
April 29, 2026 07:00 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

- European Commercialization will be Led by X4 Pharmaceuticals’ Partner, Norgine - - Global, Pivotal Phase 3 Clinical Trial Ongoing to Evaluate Mavorixafor in Chronic Neutropenia - BOSTON, April ...
April 28, 2026 19:42 ET | Source: Oruka Therapeutics, Inc.

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

MENLO PARK, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody...
April 28, 2026 07:59 ET | Source: Zion Market Research

$137.40+ BN Wearable Healthcare Devices Market Forecasts to 2034: Rising Health Awareness, Tech Advancements in Sensors & AI, and Expansion of Remote Patient Monitoring Solutions

Wearable healthcare devices market size is projected to reach USD 137.40 billion by 2034 from its value of USD 47.53 billion in 2024, at a CAGR of 11.20%
April 28, 2026 07:00 ET | Source: Benitec Biopharma Inc.

Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting

- Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-up results for the first four Cohort 1 completers, 24-month post-treatment follow-up results for the...